A study suggests the design of the Johnson & Johnson (J&J) COVID-19 vaccine may be linked to rare cases of blood clots. In fact, this vaccine is similar to the AstraZeneca vaccine, which is both adenovirus based.
The United States early last week suspended distribution of the J&J vaccine to investigate 6 cases of rare blood clots called venous sinus thrombosis (CVST), along with low blood platelet counts. This case is experienced by women under the age of 50, out of about 7 million people who have received the vaccine.
Blood clots reported in Johnson & Johnson vaccine recipients are similar to 169 European cases of AstraZeneca vaccine recipients. This British-made vaccine has been given to 34 million people in Europe.
Quoted from Reuters, Saturday (17/4/2021), The US Food and Drug Administration (FDA) is investigating whether vaccine design has anything to do with these risks.
In a letter in the New England Journal of Medicine, Johnson & Johnson scientists refuted a report published earlier last week by Kate Lynn-Muir and colleagues at the University of Nebraska. The report confirms that rare blood clots “could be linked to an adenovirus vector vaccine”.
In an interview with Reuters, top US infectious disease expert and white house adviser Dr Anthony Fauci cited the fact that these two vaccines are adenovirus vector vaccines is a clear indication of a possible link.
“I don’t know what the reason is, I can’t say for sure, but obviously this is something that raises suspicion,” Fauci said.